Sorin Group, (Reuters Code: SORN.MI)(MIL:SRN), a global company and a leader in the treatment of cardiovascular diseases, announced today that it has acquired Gish Biomedical from Ventizz Capital Partners, a private equity group focused on technology-oriented companies.
“We are excited by this opportunity to further strengthen our world leadership in providing patients and customers with the best solutions for extracorporeal circulation”
Based in California, Gish Biomedical designs and manufactures disposable medical devices for cardiovascular surgery, with a focus on the Perfusionist. Gish products have been marketed both in the United States and worldwide for over 25 years.
"We are excited by this opportunity to further strengthen our world leadership in providing patients and customers with the best solutions for extracorporeal circulation" said Michel Darnaud, President, Cardiopulmonary Business Unit and Intercontinental, Sorin Group.
The guidance previously provided to the market remains unchanged as a result of this transaction.
SOURCE Sorin Group